HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado has reiterated a 'Buy' rating on Werewolf Therapeutics (NASDAQ:HOWL) and maintained a $15 price target.
September 15, 2023 | 10:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Werewolf Therapeutics (NASDAQ:HOWL) has had its 'Buy' rating reiterated and $15 price target maintained by HC Wainwright & Co.
The reiteration of a 'Buy' rating and maintenance of a $15 price target by HC Wainwright & Co. indicates a positive outlook for Werewolf Therapeutics. This could potentially lead to an increase in investor confidence and a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100